Provided by Tiger Trade Technology Pte. Ltd.

uniQure NV

48.37
-0.5200-1.06%
Post-market: 49.000.6300+1.30%19:49 EDT
Volume:673.86K
Turnover:32.88M
Market Cap:3.36B
PE:-11.97
High:49.85
Open:48.91
Low:48.19
Close:48.89
52wk High:71.50
52wk Low:8.73
Shares:69.37M
Float Shares:57.53M
Volume Ratio:0.70
T/O Rate:1.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.0399
EPS(LYR):-3.4602
ROE:-157.61%
ROA:-15.72%
PB:10.35
PE(LYR):-13.98

Loading ...

uniQure (QURE) Is Up 6.1% After Equity Raise And FDA Backing For Accelerated HD Filing - Has The Bull Case Changed?

Simply Wall St.
·
Jun 26

UniQure Closes $259 Million Stock Offering

MT Newswires Live
·
Jun 26

Uniqure Prices Upsized Follow-on Offering of 5,686,813 Shares at $45.5 Each, Raising $259 Million Gross

Reuters
·
Jun 26

Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), uniQure (QURE)

TIPRANKS
·
Jun 25

uniQure Prices $225 Million Ordinary Stock Offering

MT Newswires Live
·
Jun 24

uniQure prices upsized public offering at $45.5 per share, raising $225 million

Reuters
·
Jun 24

Movement Alert|uniQure Rises 8.4% in Regular Trading, $150 Million Public Offering Signals Commitment to BLA Submission

Market Focus
·
Jun 24

BUZZ-U.S. STOCKS ON THE MOVE-Boundless Bio, Galectin, UniQure

Reuters
·
Jun 23

uniQure rises 7.6%

TIPRANKS
·
Jun 23

Positive Report for uniQure (QURE) from Barclays

TIPRANKS
·
Jun 23

UniQure Announces Planned $150 Million Public Offering

MT Newswires Live
·
Jun 23

uniQure launches USD 150 million follow-on share offering

Reuters
·
Jun 23

uniQure director Jack Kaye sells 5,295 shares for $225,211.35

Reuters
·
Jun 22

Analysts Are Bullish on Top Healthcare Stocks: ClearPoint Neuro (CLPT), uniQure (QURE)

TIPRANKS
·
Jun 22

uniQure publishes GenTLE Phase 1/2a AMT-260 gene therapy data in refractory MTLE###

Reuters
·
Jun 19

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now

InvestorPlace
·
Jun 19

uniQure reports preliminary data on first cohort in Phase I/IIa trial of AMT-260

TIPRANKS
·
Jun 19

uniQure reports early seizure reductions in low-dose AMT-260 Phase I/IIa trial for refractory temporal lobe epilepsy

Reuters
·
Jun 19

Why uniQure (QURE) Is Up 72.9% After FDA Backs AMT-130 Data For Accelerated Approval Prospects

Simply Wall St.
·
Jun 19

uniQure Raised to Overweight From Equal-Weight by Barclays

Dow Jones
·
Jun 19